Press Releases

YEAR
Toggle Summary Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.
- SIVEXTRO now available under Nabriva’s National Drug Code - 100% of SIVEXTRO’s net product sales to be recorded by Nabriva DUBLIN, Ireland and FORT WASHINGTON, Pa. , April 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary WEP Clinical Expands Availability Of Xenleta® (Lefamulin) Named Patient Program In Partnership With Nabriva Therapeutics
  March 24 at 8:00 AM EDT WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased to announce the expansion of the XENLETA® (lefamulin) Named Patient Program (NPP) into Australia, New Zealand, Singapore and South Africa. NPP is designed to ensure that physicians can request IV or oral
View HTML
Toggle Summary Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)
-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of oral XENLETA DUBLIN, Ireland , March 16, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:
View HTML
Toggle Summary Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates
-Relaunched XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community with 60 sales representatives- -Nabriva plans to initiate a Phase 1 clinical trial of XENLETA in patients with cystic fibrosis- -Conference call today at 4:30 p.m.
View HTML
Toggle Summary Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021
DUBLIN, Ireland , March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full
View HTML
Toggle Summary Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , March 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered
View HTML
Toggle Summary Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of
View HTML
Toggle Summary Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial Pneumonia (CABP) Treatment Guidelines
Contemporary data demonstrate macrolide resistance in S. pneumoniae is 39.5 percent overall and greater than 25 percent in most regions of the country Macrolide resistance shown to be significantly more common in outpatients vs. inpatients, with rates as high as 45.3 percent vs.
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com